Exenatide vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsCognitive Enhancement
ExenatideGLP-1 / Weight Loss Agonists
Survodutide- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- ~7 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Twice daily
- Once weekly
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —